Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIV-4 Host Tissue in hospitalized COVID-19 patients
2022-000715-31Phase 2Terminated
- Sponsor
- NEAT ID Foundation
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in coronavirus disease 2019 (COVID-19) comparing fostamatinib plus current best practice with placebo plus current best practice (2 arms). Primary endpoint: Oxygen free days through day 28. Started Jun 2022; status: terminated.
02
Drugs
fostamatinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-000715-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000715-31.